anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Epidemiologic studies have consistently shown that self -reported sleep durations of \<7 hr and \>8 hr are associated with increased mortality and morbidity. The risks associated with short sleep are consistent with a vast experimental literature indicating detrimental effects of profound sleep restriction. However, there has been little study of chronic moderate sleep restriction, which is far more common, and thus more important from a public health standpoint. The risks associated with long sleep have scarcely been experimentally examined, though epidemiological data suggest sleep restriction might promote health/longevity in long sleepers. Older adults might be more vulnerable than young adults to negative effects of further sleep impairment, perhaps particularly via inflammatory mechanisms. Negative effects might be at least as evident in long sleepers as in average sleepers if long sleep reflects underlying morbidity, as many have posited. On the other hand, older adults might tolerate (or benefit) from moderate sleep restriction. Older adults often tend to spend excessive time in bed (TIB), particularly long sleepers, and extra TIB could contribute to age-related sleep fragmentation and morbidity, which could be ameliorated with modest TIB restriction. The aims of this study are: (1) to examine the ability of older long sleepers and older average sleepers to adhere to 60 min TIB restriction; and (2) to contrast effects of 12 weeks of 60 min TIB restriction on health-related measures in older long vs. average sleepers. One hundred older adults (ages 60-80 yr) who report sleeping 8-9 hr per night and 100 adults of the same age range who report sleeping 6-7.25 hr per night will be examined at 4 experimental sites over 5 years. Following a 2-week baseline, participants will be randomly assigned to one of two 12-week treatment groups. (1) A sleep restriction group (n=60 long sleepers and n=60 average sleepers) will be assigned to a fixed sleep- wake schedule, in which time in bed is reduced precisely 60 min below each participant's baseline time in bed (TIB). (2) A control group (n=40 long sleepers and n=40 average sleepers) will have no sleep restriction, but will also follow a fixed sleep schedule. Sleep will be assessed continuously with actigraphy and a daily diary. Questionnaires will be answered. Measures will include body weight, glucose tolerance, sleepiness, depression, quality of life, psychomotor vigilance, incidence of automobile accidents, incidence of illness, and multiple markers of inflammation. Physical exams during weeks 2 and 6 of the intervention and a study ombudsman will further monitor potential adverse effects. Follow-up assessments will be conducted for 12 months. The proposed clinical trial will provide the most comprehensive Phase 1 assessment of risks and benefits of chronic moderate TIB restriction ever conducted.
The invention discloses miconazole nitrate compound vaginal effervescent tablets and a preparation method thereof. The effervescent tablets comprise miconazole nitrate, Corydalis tuber, Tricyrtis root, lightyellow Sophora root, cutch, herb of Wilson Passionflower, radix Silene tenuis, root-bark of shaggy-fruited dittany, fleeceflower root, Chinese mugwort leaf, tartaric acid, sodium carbonate, sodium bicarbonate, lauryl sodium sulfate, dextrin, and polysorbate. The preparation method includes: preparing materials, extracting effective ingredients of herbal materials, and performing granulating and tableting. The miconazole nitrate compound vaginal effervescent tablets are a Chinese and western medicine mixture, the defect that miconazole nitrate is only capable of killing germs and diminishing inflammation is effectively overcome, and the herbs are good in synergistic effect. The tablets directly act on an affected part, take effect fast, are good in effect and are convenient to use; after the effervescent tablets effervesce, a larger contact area between medicine and the human body is provided; drug effect is improved. The tablets are capable of treating both symptoms and root causes of vaginitis, quickly relieving pain and pruritus symptoms of a patient, restoring vaginal secretion and improving patient compliance.
For those randomly selected to receive mindfulness-based sex therapy, they will be asked to participate in four sessions of group therapy, over a period of 2 months. Sessions will occur in a conference room at St. Paul's Hospital. Part of the protocol of the Mindfulness - based sex therapy is that they will have a diary to be filled in. This diary will not be collected at the end of the therapy, as it is for the participant to keep. The group facilitators will be collecting session attendance.
PROBLEM TO BE SOLVED: To obtain the subject adhesive plaster capable of exhibiting excellent effects especially on the treatment of impetigo especially developed on the face and prevention of infection therewith by forming an adhesive mass layer containing a sulfa drug and having a specific ball tack value on one surface of a support. SOLUTION: This plaster is obtained by forming an adhesive mass layer containing a sulfa drug [e.g. sulfisomidin (sodium), sulfamethoxazole sodium or sulfadiazine] and having >=2 value of ball tack (a value of ball No. specified by tilted type ball tack tests in JIS Z 0237) and preferably 0.03-1 mm thickness on one surface of a support. For example, an adhesive mass prepared by adding a styrene-isoprene-styrene block copolymer to an ointment or a cream base comprising a fat, a fatty oil, lanolin, vaseline, a paraffin, a wax, a resin, a plastic, water, an emulsifying agent, a suspension, etc., is preferred as the above adhesive mass. The concentration of the sulfa drug in the adhesive mass is preferably 1-10 wt.%.
All participants will be invited to participate in a patient reported geriatric assessment questionnaire as well as an objective physical function testing. This includes the Short Physical Performance Battery (SPPB) that evaluates lower extremity performance and muscle strength assessment via hand grip dynamometer. Participants will also complete a 12 item modified version of PRO-CTCAE. This will be administered by trained research staff at the time of study enrollment. Repeat CARE instruments (Follow-up GA questionnaire and Physical Function test) will be administered after the baseline visit to measure changes in patient reported outcomes at 3 months, 6 months, and one year. A one-time blood or saliva sample will be requested and obtained at baseline or a follow-up visit.
Anesthesia objectives have evolved into combining hypnosis, amnesia, analgesia, paralysis, and suppression of the sympathetic autonomic nervous system. Technological improvements have led to new monitoring strategies, aimed at translating a qualitative physiological state into quantitative metrics, but the optimal strategies for depth of anesthesia (DoA) and analgesia monitoring continue to stimulate debate. Historically, DoA monitoring used patient's movement as a surrogate of awareness. Pharmacokinetic models and metrics, including minimum alveolar concentration for inhaled anesthetics and target-controlled infusion models for intravenous anesthesia, provided further insights to clinicians, but electroencephalography and its derivatives (processed EEG; pEEG) offer the potential for personalization of anesthesia care. Current studies appear to affirm that pEEG monitoring decreases the quantity of anesthetics administered, diminishes postanesthesia care unit duration, and may reduce the occurrence of postoperative delirium (notwithstanding the difficulties of defining this condition). Major trials are underway to further elucidate the impact on postoperative cognitive dysfunction. In this manuscript, we discuss the Bispectral (BIS) index, Narcotrend monitor, Patient State Index, entropy-based monitoring, and Neurosense monitor, as well as middle latency evoked auditory potential, before exploring how these technologies could evolve in the upcoming years. In contrast to developments in pEEG monitors, nociception monitors remain by comparison underdeveloped and underutilized. Just as with anesthetic agents, excessive analgesia can lead to harmful side effects, whereas inadequate analgesia is associated with increased stress response, poorer hemodynamic conditions and coagulation, metabolic, and immune system dysregulation. Broadly, 3 distinct monitoring strategies have emerged: motor reflex, central nervous system, and autonomic nervous system monitoring. Generally, nociceptive monitors outperform basic clinical vital sign monitoring in reducing perioperative opioid use. This manuscript describes pupillometry, surgical pleth index, analgesia nociception index, and nociception level index, and suggest how future developments could impact their use. The final section of this review explores the profound implications of future monitoring technologies on anesthesiology practice and envisages 3 transformative scenarios: helping in creation of an optimal analgesic drug, the advent of bidirectional neuron-microelectronic interfaces, and the synergistic combination of hypnosis and virtual reality.
Participants will engage in their outpatient treatment program as-usual,but additionally complete 6 weekly, hour-long visits to complete questionnaires. They will complete 6 weeks of treatment (6 sessions total).
1,242,882. Anti-inflammatory compositions. BYK-GULDEN LOMBERG CHEMISCHE FABRIK G.m.b.H. 17 Oct., 1968 [18 Oct., 1967], No. 49229/68. Heading A5B. Pharmaceutical compositions, having antiinflammatory activity and particularly useful for the treatment of rheumatic diseases, comprise a pharmaceutically acceptable carrier and a salt of a substituted malonic acid hydrazide that has been obtained by the process claimed in Specification 1,164,039, the salt having the general formula wherein R is a straight chain, branched or cyclic alkyl or alkenyl radical having up to 10 carbon atoms and optionally interrupted by an oxygen, sulphur or imino group, an aryl or aralkyl wherein the aromatic ring is optionally substituted by halogen, hydroxy, alkoxy, nitro, amino, or dialkylamino, R 1  is hydrogen or any of the radicals defined for R, Ar is phenyl which is optionally substituted by halogen, alkyl and/or alkoxy groups of up to 3  carbon atoms inclusive or hydroxy and X is a metal other than sodium, n being the valency of the metal, or X is the ammonium radical or a quarternary ammonium radical in which at least one of the hydrogen atoms of the ammonium radical is replaced by optionally substituted alkyl or aralkyl. The compositions may be in the form of a dragee, tablet, syrup, ointment, suppository or injection solution and may include' another pharmacodynamically active substance such as fever-reducing substances, anti-allergic substances and inflammation-inhibiting agents such as prednisolone.
Wound healing is an obvious clinical concern that can be hindered by inadequate angiogenesis, inflammation, and chronic hypoxia. While exosomes derived from adipose tissue-derived stem cells have shown promise in accelerating healing by carrying therapeutic growth factors and microRNAs, intracellular cargo delivery is compromised in hypoxic tissues due to activated hypoxia-induced endocytic recycling. To address this challenge, we have developed a strategy to coat oxygen nanobubbles with exosomes and incorporate them into a polyvinyl alcohol/gelatin hybrid hydrogel. This approach not only alleviates wound hypoxia but also offers an efficient means of delivering exosome-coated nanoparticles in hypoxic conditions. The self-healing properties of the hydrogel, along with its component, gelatin, aids in hemostasis, while its crosslinking bonds facilitate hydrogen peroxide decomposition, to ameliorate wound inflammation. Here, we show the potential of this multifunctional hydrogel for enhanced healing, promoting angiogenesis, facilitating exosome delivery, mitigating hypoxia, and inhibiting inflammation in a male rat full-thickness wound model.
Lung cancer is the most common cancer in the world. In operable early stage patients NSCLS can be curable, but even after complete primary tumor resection, about 45% of early stage patients develop local or distant recurrence within 8-18 months. Recent studies have established that targeted therapies may fail to cure the disease because of tumor heterogeneity. The presence of genetic heterogeneity in different portions of a tumor have demonstrated its importance in tumor biology suggesting that pre-existing genetically different sub clones may be selected by therapy or differentially involved in the metastatic process, leading to treatment failure.

The relationship of tumor heterogeneity with the poor clinical outcome suggests that its assessment could provide interesting and useful clinical information, especially, in terms of prognosis and treatment selection. It is now, well established that during the evolution of tumor new cellular clones could be emerged which differ genetically from the molecular signature of tumor cells evaluated at the time of initial diagnosis. This molecular evolution may further contribute to the tumor heterogeneity during the disease progression. The evaluation of the real-time molecular tumor heterogeneity requires repeated re-biopsies during the different clinical phases of NSCLC which, however, are invasive and not, always, feasible. This problem can be by-passed by the use of tumor-originating elements in the plasma and among these cellular products the isolation and analysis of cell tumor DNA (ctDNA) and the characterization of Circulating Tumor Cells (CTCs) represent important tools for identification and monitoring of molecular tumor alterations in cancer patients, representing what the investigators call "liquid biopsy". ctDNA is originated from cellular necrosis due to increased tumoral cellular turnover and cellular ischemia as well as from apoptosis of tumor cells or lysis of Circulating Tumor Cells (CTCs). On the other hand, the CTCs, which designate the cells circulating in the blood, can be detected in several tumor types, irrespectively of the clinical phase, and their detection has been correlated with disease progression and treatment resistance. Therefore, the concomitant analysis of both ctDNA and CTCs could permit to better evaluate the genetic heterogeneity of the tumor since they continuously released from tumor cells throughout the clinical course of the disease and is considered to be proportional to tumor burden and tumor progression at each time-point.

This is a multicenter, single arm, non-randomized translational research study. Patients with operable NSCLC will be enrolled in the study. Patients' peripheral blood will be obtained before the surgical excision of the primary tumor as well as 1-month post-op and every 3-6 months thereafter until disease progression and upon disease relapse for the evaluation of ctDNA and CTCs. Different sites of the primary tumor as well as the regional involved lymph nodes and, in selected patients, biopsies from metastatic sites will be genotyped by NGS as well.
PURPOSE: To facilitate the diagnosis of malignant tumor by connecting a free or compounded recognine to anti-recognine antibody in a sample. CONSTITUTION: Tumor tissue cells are extracted by neutral buffer solution to dissolve protein fraction, and the fraction with pH of about 1 to 4 is separated from the obtained protein solution extract. Recognines such as astrocytin and malignin having molecular weights of about 8000 and 10000, respectively are separated. These recognines are connected to carrier such as bromoacetylcellulose as a target reagent. Serum sample is added to target reagent suspension, and the protein connected to the reagent is separated and determined. Thus, he diagnosis of the malignant can be facilitated.
Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The metalloid arsenic, known for its toxic properties, is widespread presence in the environment. Our previous research has confirmed that prolonged exposure to arsenic can lead to liver fibrosis injury in rats, while the precise pathogenic mechanism still requires further investigation. In the past few years, the Nod-like receptor protein 3 (NLRP3) inflammasome has been found to play a pivotal role in the occurrence and development of liver injury. In this study, we administered varying doses of sodium arsenite (NaAsO2) and 10 mg/kg.bw MCC950 (a particular tiny molecular inhibitor targeting NLRP3) to Sprague-Dawley (SD) rats for 36 weeks to explore the involvement of NLRP3 inflammasome in NaAsO2-induced liver injury. The findings suggested that prolonged exposure to NaAsO2 resulted in pyroptosis in liver tissue of SD rats, accompanied by the fibrotic injury, extracellular matrix (ECM) deposition and liver dysfunction. Moreover, long-term NaAsO2 exposure activated NLRP3 inflammasome, leading to the release of pro-inflammatory cytokines in liver tissue. After treatment with MCC950, the induction of NLRP3-mediated pyroptosis and release of pro-inflammatory cytokines were significantly attenuated, leading to a decrease in the severity of liver fibrosis and an improvement in liver function. To summarize, those results clearly indicate that hepatic fibrosis and liver dysfunction induced by NaAsO2 occur through the activation of NLRP3 inflammasome-mediated pyroptosis, shedding new light on the potential mechanisms underlying arsenic-induced liver damage.
MK-3102-006-Ext 1 added a 66-week extension to the base study (MK-3102 P006) to assess the long-term safety and tolerability of omarigliptin. To be eligible for the extension, participants must complete the double-blind base study, must have had at least a 75% compliance with study drug during the base study and can not meet any of the criteria for discontinuation. Participants randomized to placebo in the base study will be switched in a blinded manner to pioglitazone 30 mg once daily, in the extension study prior to implementation of amendment P006-13. Once amendment P006-13 has been IRB/IEC approved and blinded metformin drug supply is available at the site, participants will be switched from pioglitazone to metformin, starting at 500 mg once daily and titrated up to 1000 mg twice daily. Participants with a contraindication to metformin will be discontinued from the study. Participants randomized to 0.25 mg, 1 mg, 3 mg, and 10 mg of omarigliptin in the base study will be switched to omarigliptin 25 mg; those randomized to 25 mg of omarigliptin in the base study will continue on the same dose in the extension study. After the clinical dose of omarigliptin selected for further development has been identified based upon the results of the base study, all participants randomized to omarigliptin will be switched to the identified clinical dose.
The invention discloses a method for preparing a polylactic acid microneedle based on fused deposition and a polylactic acid microneedle, which are based on the technology of preparing a biocompatible polylactic acid microneedle structure by fused deposition and matched with hydrolytic etching, and the subsequent step of reducing a columnar structure by hydrolyzing polylactic acid to enable the columnar structure to reach the microneedle size, thereby having positive significance for simplifying microneedle processing difficulty and popularizing microneedle application. The prepared polylactic acid microneedle has enough mechanical strength to pierce animal skin tissues. The drug can be coated on the surface of the polylactic acid microneedle and enters the dermis layer along with the microneedle. Due to the top-down processing mode, the inclination of the polylactic acid column body prepared by fused deposition can be customized. The subsequent hydrolytic etching only reduces the size of the polylactic acid column and does not change the gradient of the initial design. The processing method is simple and reasonable in process, does not need a large amount of labor cost, and enables scientific researchers to produce the microneedles in a large scale for scientific research even under the background without the micro-processing professional knowledge.
This is an 8-week educational and supportive therapy group intervention delivered via telehealth. It consists of psychoeducation, relaxation, discussion, and weekly therapeutic exercises and assignments (i.e., homework).
The invention relates to a novel and improved nanoparticulate form of a frankincense gum extract, containing, inter alia, Boswellic acids and/or their derivatives. The nanoparticles have advantageous properties for use in the treatment of inflammatory diseases. Surprisingly, these advantages are obtained both in topical application and oral administration. When used in topical formulations, the nanoparticles are better absorbed by the skin than are known, tacky extracts, and they are thus suitable for the treatment, for example, of neurodermatitis and/or actinic keratosis and/or basal cell carcinoma and/or epithlioma and/or squamous cell carcinoma of the skin. For example, in soft gel capsules that dissolve in the small intestine, the nanoparticles have much improved bioavailability, which also considerably improves oral administration for treatment of inflammatory conditions. Finally, the nanoparticles can also be used for coating stents and implants.
The proposed research will use a multi-disciplinary expertise of the University of Florida Sepsis and Critical Illness Research Center (SCIRC). For this project, the investigators will take advantage of the SCIRC's ongoing recruitment and monitoring of sepsis patients into an observational 1-year follow-up study. For this pilot, the investigators will approach and screen older sepsis survivors who get discharged from hospital to home. Potential participants will be approached within 5 days before discharge. The study will enroll 40 low-functioning (SPPB \<6) older sepsis patients (≥55 years old). The enrolled subjects will be randomized to either digitally delivered and home-based exercise training program or standard care control group. All participants will receive tablets with the Blue Marble Health Platform (BMHP) app. For the control group, the app will be enabled only for the physical function assessments and for the rest of the time, only a health diary for logging daily activities will be available. Both groups will receive weekly phone calls from our research staff member to ask about their health and remind them of weekly charging of their tablets. The intervention group will receive daily reminders by text to perform the exercises for 30 min daily 5 days/week. Participants will be given wrist fitness tracking watches with step-counting and heart rate to measure adherence to an exercise intervention. At baseline and 12-week follow-up visits physical function assessments will be app-guided using the BMHP-validated physical function test similar to SPPB, with a blinded coordinator present via a video call to assist a participant with answering questions about the tests. The interventionists who will be calling the participants will be trained to maintain the same level of rapport to not jeopardize the study conditions.
TRI-LUMA Cream is NOT indicated for the maintenance treatment of melasma. After achieving control with TRI-LUMA Cream, some patients may be managed with other treatments instead of triple therapy with TRI-LUMA Cream. Melasma usually recurs upon discontinuation of TRI-LUMA Cream.

The safety and efficacy of TRI-LUMA Cream in patients of Fitzpatrick Skin Types V and VI have not been studied. Excessive bleaching resulting in undesirable cosmetic effect in patients with darker skin cannot be excluded.

The safety and efficacy of TRI-LUMA Cream in the treatment of hyperpigmentation conditions other than melasma of the face have not been studied.

Because pregnant and lactating women were excluded from, and women of childbearing potential had to use birth control measures in the clinical trials, the safety and efficacy of TRI-LUMA Cream in pregnant women and nursing mothers have not been established [ see Use in Specific Populations (8.1, 8.3)].